ELON, KVHI, TEAR, KYN, KOOL: Friday's Active Stocks
(EMAILWIRE.COM, March 06, 2011 ) Dallas, TX -- Echelon Corp. (NASDAQ:ELON) has lost 0.8% or seven cents a share to settle at $8.73 with a volume of 79,000 shares. For the past 52 weeks the stock has been trading between $6.90 and $10.75 with an average volume of 200,423. Company has a market capitalization of $363 million.
Echelon Corporation develops, markets, and sells system and network infrastructure products. In the building, home, industrial, transportation and other automation markets, the Company sells a line of control networking products to original equipment manufacturers (OEMs). OEMs design in, or embed the Company's products into their products and systems. The Company's line of LonWorks Infrastructure (LWI) network infrastructure products include transceivers, control modules, routers, network interfaces, development tools, and software tools and toolkits. For system integrators serving the street lighting, remote facility monitoring, and energy management markets, it has developed the i.LON SmartServer family of energy management products
KVH Industries (NASDAQ:KVHI) has lost 2.5% or $.35 a share to settle at $13.91 with a volume of 79,000 shares. for the past 52 weeks the stock has been trading between $10.76 and $16.66 with a average volume of 100,000 shares and a market cap of $200 million dollars.
KVH Industries, Inc. (KVH) is a manufacturer of solutions that provide global high-speed Internet, television, and voice services via satellite to mobile users at sea, on land and in the air. It is also a manufacturer of navigational sensors and integrated inertial systems for defense and commercial guidance and stabilization applications. It sells its mobile communications products and airtime services, including the TracVision and TracPhone systems and mini-VSAT Broadband airtime, through an international network of distributors and retailers worldwide.
TearLab (NASDAQ:TEAR) has gained 2.31% or five cents a share to settle at $2.22 with an exploding volume of 170,000 shares. For the past 52 weeks the stock has been trading between $1.10 and $5.14 with an average volume of 32,000 shares. Company has a market cap of $32.7 million.
TearLab Corp., formerly OccuLogix, Inc., is an in-vitro diagnostic company based in San Diego, California. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. Its subsidiary is TearLab, Inc.
Kayne Anderson (NYSE:KYN) has lost 0.83% or $.26 to settle at $30.97 a share with a volume of 74,000. For the past 52 weeks the stock has been trading between $20.50 and $31.63 with a market cap of $2.1 billion and a P/E ratio of 3.8 for the trailing 12 months.
Kayne Anderson MLP Investment Company is a non-diversified, closed-end company. The Company's investment objective is to obtain a high after-tax total return by investing at least 85% of its total assets in energy-related master limited partnerships (MLPs) and their affiliates, and in other companies that operate assets used in the gathering, transporting, processing, storing, refining, distributing, mining or marketing of natural gas, natural gas liquids, crude oil, refined petroleum products or coal (collectively with MLPs referred to as Midstream Energy Companies).
ThermoGenesis (NASDAQ:KOOL) slighted 12.21% or $.32 a share to settle at $2.30 with a volume of 780,000, compared to its average three-month volume of 147,000 shares. For the past 52 weeks the stock has been trading between $1.60 and $3.95 with a market cap of $32.4 million.
ThermoGenesis Corp. design, develop and commercialize medical products that enable the collection, processing and cryopreservation of stem cells and other cellular tissues used in the practice of regenerative medicine. Its products automate the volume reduction and cryopreservation process of adult stem cell concentrates from cord blood and bone marrow for use in laboratory and point of care settings. As of June 30, 2010, the Company sells its products in 37 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. The Company provides the tools necessary for the collection, separation, storage and delivery of stem cells from adult tissue sources, including cord blood and bone marrow, and in the future, adipose and placenta.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any current or recent stocks listed in this stock news report